Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells

Seth W Perry*, Jill M Schueckler, Kathleen Burke, Giuseppe L Arcuri and Edward B Brown

Abstract

Background: Matrix metalloproteases and collagen are key participants in breast cancer, but their precise roles in cancer etiology and progression remain unclear. MMP13 helps regulate collagen structure and has been ascribed largely harmful roles in cancer, but some studies demonstrate that MMP13 may also protect against tumor pathology. Other studies indicate that collagen’s organizational patterns at the breast tumor-host interface influence metastatic potential. Therefore we investigated how MMP13 modulates collagen I, a principal collagen subtype in breast tissue, and affects tumor pathology and metastasis in a mouse model of breast cancer.

Methods: Tumors were implanted into murine mammary tissues, and their growth analyzed in Wildtype and MMP13 KO mice. Following extraction, tumors were analyzed for collagen I levels and collagen I macro- and micro-structural properties at the tumor-host boundary using immunocytochemistry and two-photon and second harmonic generation microscopy. Lungs were analyzed for metastases counts, to correlate collagen I changes with a clinically significant functional parameter. Statistical analyses were performed by t-test, analysis of variance, or Wilcoxon-Mann–Whitney tests as appropriate.

Results: We found that genetic ablation of host stromal MMP13 led to: 1. Increased mammary tumor collagen I content, 2. Marked changes in collagen I spatial organization, and 3. Altered collagen I microstructure at the tumor-host boundary, as well as 4. Increased metastasis from the primary mammary tumor to lungs.

Conclusions: These results implicate host MMP13 as a key regulator of collagen I structure and metastasis in mammary tumors, thus making it an attractive potential therapeutic target by which we might alter metastatic potential, one of the chief determinants of clinical outcome in breast cancer. In addition to identifying stromal MMP13 as an important regulator of the tumor microenvironment and metastasis, these results also suggest that stromal MMP13 may protect against breast cancer pathology under some conditions, a finding with important implications for development of chemotherapies directed against matrix metalloproteases.

Keywords: Two-photon, Microscopy, Cancer, Second harmonic generation, Collagen, SHG, Tumor, MMP, Matrix metalloprotease, MMP-13, Intravital, Imaging, In vivo, Multiphoton, Intrinsic, Fluorophore
Background

The structure and function of tumor extracellular matrix (ECM) play critical roles in cancer initiation and outcome [1,2]. More specifically, organization or reorganization of collagen, a key structural component of the ECM, has been shown to be an important factor in tumor genesis, progression, and/or metastasis [3-9]. Tumor cells have been shown to migrate preferentially along aligned collagen fibers [10,11], and others have reported particular “tumor associated collagen signatures” (TACS) – i.e. patterns of collagen alignment around the tumor boundary – that may be associated with breast cancer tumor invasion into host stroma [5] and patient survival [12]. However specific functional mechanisms or molecular mediators that lead to such collagen reorganizations, with consequent effects on tumor progression and metastasis, remain largely undefined and would represent attractive novel therapeutic targets for breast cancer.

Some likely mediators of collagen structure at the tumor-host interface are matrix metalloproteases (MMPs). MMPs are key regulators of the ECM and collagen remodeling [13,14], and are also frequently implicated in cancer [15]. MMP-13 (collagenase-3) was originally isolated from human breast cancer tissue [16], and has been shown to be an important contributor to breast (and other) cancer pathology [15,17,18]. As a collagenase with fairly broad substrate specificity, MMP-13 is capable of cleaving several collagen subtypes including fibrillar collagens I, II, and III [15]. These fibrillar collagens are detectable by second harmonic generation (SHG) microscopy, an optical imaging approach that is increasingly being used to provide diagnostic insights into cancer biology [9], and which has been used extensively in TACS analysis [5,12,19]. Collagen I is the most abundant fibrillar collagen in mammals [20], is a substrate for MMP-13 [15], and is typically increased in breast tumor- versus normal mammary gland-associated stroma [21,22]. Finally, Col1a1 transgenic mice with degradation resistant collagen I have been used for TACS analysis of increased collagen deposition in a mammary tumor model [19]. Therefore, in this study we sought to determine whether direct in vivo genetic manipulation of host MMP-13 alters collagen I organization at the mammary tumor-host boundary (i.e. TACS), with demonstrable effects on tumor metastasis.

Methods

Cells and reagents

Murine medullary mammary adenocarcinoma (E0771) cells syngeneic with C57BL/6 mice (Roswell Park Cancer Institute, Buffalo, NY) were grown in RPMI 1640 medium (Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% gamma-irradiated defined fetal bovine serum (HyClone/Thermo-Fisher, Waltham, MA) and 100 ug/ml Primocin antibiotic (InvivoGen, San Diego, CA). For mammary tumor implantation experiments, cells were harvested in 0.25% trypsin/EDTA, centrifuged, re-suspended in sterile PBS, and kept on ice until implantation into a mammary fat pad.

Tumor implantation

Congenic female C57BL/6 wildtype (WT) or MMP-13 knockout (MMP13 KO) mice [23] were used for E0771 tumor implantation experiments at 15–19 weeks of age. Animals were anesthetized with ketamine/xylazine (90/9 mg/kg) delivered intraperitoneally (i.p.). The animals’ ventral surfaces were depilated, followed by implantation of $1 \times 10^6$ E0771 mammary tumor cells into the right inguinal mammary fat pads using a 27-gauge needle. Caliper-measured tumor sizes were recorded on days 12, 19, and 28 of the experiments. On Day 28 post-implantation, animals were sacrificed by i.p. sodium pentobarbital injection and subsequent cervical dislocation. The E0771 mammary tumors were excised, and immediately snap-frozen on dry ice for subsequent cryosectioning and immunohistochemistry. Lungs were excised, fixed in 10% neutral-buffered formalin, then paraffin embedded, sectioned, and hematoxylin-eosin (H&E) stained for analysis of lung metastases. Procedures were performed in accordance with the University Committee on Animal Resources (UCAR).

Immunohistochemistry

Snap-frozen tumors were cryo-sectioned (−21°C) at 20 um, then static-mounted on positively charged slides. For immunohistochemistry (IHC), sections were cold-fixed (−20°C) for 20 minutes in 3:1 acetone/methanol, rehydrated 2 × 5 minutes in sterile PBS, then blocked for one hour (5% BSA, .2% Triton-X 100 in PBS). Primary antibody for Collagen I (Abcam #21286, Cambridge, MA) was then applied for 2 hours at room temperature in a humidified chamber, diluted 1:200 in 0.5% BSA, .2% Triton-X 100 in PBS, followed by 2 × 5 minutes PBS wash, then two hours of Alexa Fluor 594-conjugated goat anti-rabbit IgG (1:500 in the same diluent as the primary; Invitrogen, Carlsbad, CA). Optimal antibody dilutions and incubation times were pre-determined empirically. Following staining for Collagen I protein, tumor sections were washed and mounted in ProLong Gold Antifade reagent (without DAPI; Invitrogen, Carlsbad, CA), then allowed to dry for 24 hours before imaging. Similar procedures were used for IHC against MMP-13 (Millipore #ab8120, Billerica, MA).

Imaging and image analysis

Slides were imaged by a blinded observer using a custom-built multi-photon microscope. A Mai Tai Titanium:sapphire laser (Newport/Spectra Physics, Santa...
Clara, CA) provided two-photon (2P) excitation (100 fs pulses at 80 MHz and 810 nm) for simultaneously epidetecting backwards-directed SHG (B_{SHG}) and immunofluorescence (IF) signals from Collagen I fibers in the excised mammary tumors. Beam scanning and image acquisition were performed with a custom-modified Fluoview FV300 confocal scanner interfaced with a BX61WI upright microscope (Olympus, Center Valley, PA), with an Olympus XLMPLFL20X/W water immersion lens (20×, 0.95 N.A.). Backscattered SHG (HQ405/30m-2P emission filter, Chroma, Rockingham, VT; HC125-02 PMT, Hamamatsu Corporation, Hamamatsu, Japan) and 2P-excited Collagen I IF (Chroma HQ635/30 m-2P emission filter; HC125-01 Hamamatsu PMT) signals were separated from the 810 nm excitation beam by a short pass dichroic mirror (Chroma 670 DCSX), and simultaneously captured in two distinct channels (using a 475 DCSX Chroma long pass dichroic, and the emission filters and PMTs above) on every scan. Resulting two-channel (B_{SHG} and IF) images are 680 microns across. Laser power was monitored and kept constant throughout each experiment and across experimental repetitions, as were PMT voltage, gain, and offset.

Because MMP13 was knocked out from the host animal, for the results described herein we analyzed images representing random tumor-host interface regions, i.e. random “outer edge” regions of tumors. Images from these areas were obtained as z-stacks (1 um step size) taken over the entire 20 um thickness of the tissue section. For each channel (B_{SHG} and collagen I IF), maximum projection images were taken from each stack, then image analysis was performed with ImageJ as follows. For each slide (usually 2–3 tumor sections/slide) and for each channel, background was defined by the average pixel counts of a laser-excited image taken from an area of the slide with no tissue, and subtracted from the raw B_{SHG} and IF images. These background corrected images were used for image analysis in ImageJ. For assessment of collagen I protein levels, mean pixel intensity of collagen I IF was measured over the tumor periphery FOVs. For coherency analysis, the coherency parameter (see below, and [24–26]) was calculated on these same collagen I IF images using the ImageJ plugin Orientation (open source, written by Daniel Sage, Biomedical Image Group, EPFL, Switzerland; http://bigwww.epfl.ch/demo/orientation/). This coherency parameter was quantified on a pixel-by-pixel basis, then averaged over all pixels in an image to produce a single coherency value for each image, which could then be averaged across all images in each experimental group. For normalized SHG calculations (i.e. B_{SHG} normalized to collagen I IF), the B_{SHG} and collagen I IF images were thresholded to select for collagen I-positive features and to reduce artifactual effects from non-specific background in either channel, applying the same thresholding standard to images from all experimental groups. The B_{SHG} channel was then “masked” to the thresholded collagen I IF channel, so that only SHG pixels that were also positive for collagen I immunofluorescence were analyzed. Dividing the mean B_{SHG} pixel intensity from these masked B_{SHG} images, by the mean IF pixel intensity from the corresponding Collagen I IF images from the same FOV, produces a ratiometric value which represents B_{SHG} normalized to Collagen I protein levels on a pixel-by-pixel basis over the exact same XYZ pixel space, for each tumor periphery image. This method of analysis allows us to analyze only the B_{SHG} signal that is primarily restricted to collagen I, and provides a “normalized” B_{SHG} value for collagen I. Since SHG is sensitive to both collagen microstructural properties and collagen abundance [9,27], this “normalized” B_{SHG} parameter allows us to primarily assess changes in collagen I microstructural properties with reduced sensitivity to changes in collagen I expression levels, and similar strategies have been employed by others previously [28,29]. To calculate the forward SHG (F_{SHG}) to B_{SHG} ratio (F_{SHG}/B_{SHG}), both F_{SHG} and B_{SHG} were captured simultaneously above (B_{SHG}) and below (F_{SHG}) the slide specimen in two channels using the microscope setup previously described [30]. F_{SHG} and B_{SHG} images were simultaneously collected as stacks of 11 images spaced 3μm apart, within a 660 μm field of view. Four images were taken from each tumor sample around the tumor boundary at the tumor-host interface, with 2 tumor samples analyzed per animal from the same cohorts of WT and MMP13 KO animals. Image analysis was conducted with ImageJ. Each stack was maximum intensity projected, serving as an “autofocus” for the effectively single layer of collagen. Projected images were background subtracted using a maximum intensity projection of a matching 11 image scan taken with a closed shutter, then background subtracted F_{SHG} and B_{SHG} images were divided to create an F_{SHG}/B_{SHG} ratio image. For each image a common threshold was applied to all images to distinguish collagen pixels from background pixels and to select for fibers likely to be collagen I, and subthreshold background (i.e. non collagen fiber) pixels were excluded from analysis by binary masking. The average pixel value these non-background collagen fiber pixels was calculated from all F_{SHG}/B_{SHG} ratio images in the same cohort of MMP13 KO and WT animals, and expressed as mean F_{SHG}/B_{SHG} ± SEM.

**Evaluation of lung metastases**

For evaluation of lung metastases, lungs were excised from tumor bearing experimental animals as described above, fixed in 10% neutral-buffered formalin, then paraffin embedded. Five-micron rotary microtome sections
were taken through both lobes of the lung, mounted on positively charged slides, then H&E stained. H&E-stained lung sections were evaluated for lung metastases by a trained blinded observer using brightfield microscopy (Olympus BX-51, Center Valley, PA). Metastatic infiltrating tumor cells were identified by several criteria including: high ratio of hematoxylin relative to eosin, surrounding abnormalities in lung structure, abnormal shape/size of nuclei and/or presence of abnormal mitotic spindles, and differences in cell shape and size, with ≥ 1 infiltrating tumor cells counted as a metastatic event. Results are presented as mean number of lung metastases/cm² ± SEM for each treatment group.

Statistical analysis
Statistical analysis was performed using Kaleidagraph (Synergy Software, Reading, PA) or Prism 5 (GraphPad Software, La Jolla, CA) software. Student’s t-tests (unpaired), ANOVA with protected Fisher LSD post-tests for planned comparisons, or Wilcoxon-Mann–Whitney tests were used for statistical analyses as appropriate. p-values ≤ .05 were considered significant.

Results
Stromal MMP13 knockout increases mammary tumor Collagen I content, but decreases Collagen I ordering, at the tumor-host interface
Murine medullary breast adenocarcinoma (E0771) tumor cells were implanted into mouse mammary fat pads for 28 days. Consistent with other reports [31], MMP13 KO did not alter mammary tumor size in our E0771 mammary tumor model (Figure 1). MMP-13 expression was decreased in tumors from the MMP13 KO mice versus WT (Additional file 1: Figure S1A) and moreover, in the WT but not MMP13 KO mice, MMP13+ cell bodies were found around the tumor periphery which suggested the presence of peritumor (and possibly infiltrating) MMP13+ stromal cells in WT but not MMP13 KO mice (compare Additional file 1: Figures S1B and S1C, respectively). Also at the tumor periphery, Collagen I protein levels were significantly increased in MMP13 KO versus wildtype animals as quantified by immunofluorescence staining (Figure 2), suggesting that depletion of this collagen degrading enzyme from host cells increases tumor Collagen I content. However, despite this increase in Collagen I content at the tumor boundaries in the MMP13 KO mice, overall collagen ordering at tumor boundaries was decreased (i.e. more random) in these MMP13 KO mice versus WT controls. Figure 3 highlights the decreased ordering in MMP13 KO mice, with WT mice demonstrating many robust Collagen I fibers more frequently oriented parallel to the tumor boundary, closely resembling a TACS-2 arrangement as previously described [5,12,19] (Figure 3A). Compared to these WT mice, MMP13 KO mice in contrast, although they had greater overall collagen I content (Figure 1), displayed fewer robust linear collagen I fibers, and a more randomly oriented collagen I distribution closely resembling a TACS-1 arrangement (Figure 3B). In adjacent sections of the same WT tumor as shown in Figure 3A, antibody labeling for MMP13 around the tumor periphery appeared to be closely localized with the robust TACS-2 patterned Collagen I fibers oriented parallel to the tumor boundary (Additional file 2: Figure S2), thus further implicating MMP-13 as likely to be a key orchestrator of these observed TACS changes in Collagen I organization.

To quantify these differences in local orientations of collagen I fibers, we performed tensor analysis of local image structure to calculate the coherency parameter (C), which is the ratio of the difference and sum of the largest (λmax) and smallest (λmin) tensor eigenvalues (averaged for all pixels over the image FOV), as follows:

\[ C = \frac{\lambda_{\text{max}} - \lambda_{\text{min}}}{\lambda_{\text{max}} + \lambda_{\text{min}}} \]  

(1)

With the upper bound C = 1 indicating highly oriented structures, and the lower bound C = 0 indicating high isotropy [24-26]. This analysis clearly indicated that Collagen I in mammary tumor peripheries of WT mice was more highly oriented (i.e. more ordered; C closer to 1),
than in the mammary tumor peripheries of MMP13 KO mice (less ordered, C closer to 0) (Figure 4). Figure 5 shows a pseudo-colored map of these coherency values using the same images as in Figure 3 (more visible bright red areas = higher coherency).

Together these results suggest that depletion of host (stromal) MMP13 – a key collagen degrading enzyme – increased total collagen I content, but reduced collagen I organization, in the periphery of E0771 mammary tumors grown in MMP13 KO versus WT mice.

**Stromal MMP13 knockout alters Collagen I microstructure at the tumor-host interface**

SHG results when two photons (e.g. as provided by the near-IR titanium sapphire laser in a multiphoton microscope), interacting simultaneously with a non-centrosymmetric target such as collagen fibers, combine to produce a new photon with exactly twice the energy and half the wavelength of the interacting photons [9,32-36]. As a coherent phenomenon, SHG is intrinsically sensitive to spacing and regularity of scatterers, and hence can be utilized to detect changes in several aspects of collagen microstructure including regularity of the arrangement of collagen fibrils within larger collagen fibers; interfibril spacing; and fibril diameter, tilt angle, or pitch angle [4,7,9,27,34,37-41]. Collagen I is a particularly strong SHG emitter in vivo [7], is a substrate for MMP13 [15], is increased in breast cancer stroma [21,22], and is an important contributor to TACS [19].

Figures 2, 3, 4 and 5 assessed collagen I macrostructural properties (i.e. gross fiber orientations and arrangement)
at the tumor-host interface, and to further these findings, we now wished to analyze collagen I microstructural properties at the tumor-host interface as assessed by SHG. For these reasons, we restricted our SHG analysis to the intensity of SHG signals emanating primarily from collagen I fibers, specifically using the “normalized BSHG” as described in Methods to provide an SHG measure of collagen I microstructural properties independent of changes in collagen I protein levels, as well as to gain particular insight into changes in the effective diameter or packing arrangement/density of fibrils within the SHG focal volume [4, 27, 30, 34, 42].

Figures 3, 4 and 5 demonstrated that while tumors in both WT and MMP13 KO mice contained both “diffuse” and “large fiber” patterns of collagen I, there was proportionately more “diffuse” collagen I with apparently thinner fiber structure or bundling on average in MMP13 KO tumors, versus proportionately more “large fiber” collagen I in WT tumors (often ordered parallel to the tumor boundary resembling a TACS-2 signature, e.g. Figure 3A). Therefore we hypothesized that knockout of MMP13 collagenase activity could cause differences in collagen I microstructural properties – e.g. regularity or density of collagen fibrils within larger collagen fibers; fibril spacing; and fibril diameter, tilt angle, or pitch angle [4, 7, 9, 27, 34, 37-41] – which might in turn account for the different collagen I macrostructural phenotypes observed in MMP13 KO versus WT mice.

As described here and in Methods, we measured collagen I-normalized BSHG in the same WT and MMP13 KO animals and tumor-host interface regions as depicted in Figures 1, 2, 3, 4 and 5. We found that normalized BSHG was significantly higher in the E0771

![Figure 4 Coherency maps of decreased Collagen I ordering at the E0771 mammary tumor boundary in MMP13 KO mice.](image-url)

WT and MMP13 KO mice were implanted with E0771 mammary tumors as described, and images of anti-Collagen I immunofluorescence staining at the tumor-host interface were obtained as described in Figure 3. As described in Methods and Results, to quantitatively assess Collagen I ordering we calculated the mean coherency parameter averaged over all pixels in each image, thus producing a single coherency value for each image. This coherency value for each image was averaged for n=16 (WT) and n=14 (MMP13 KO) tumor boundary FOV images (± SEM) from the same cohort of animals to produce this plot. Mean coherency was significantly decreased in the MMP13 KO versus WT mice (*p < .007), reflecting less organized (more randomly oriented) collagen I structure. Coherency values for each image were produced using OrientationJ (http://bigwww.epfl.ch/demo/orientation/), then graphed in Kaleidagraph (Synergy Software, Reading, PA).

![Figure 5 Coherency maps of decreased Collagen I ordering at the E0771 mammary tumor boundary in MMP13 KO mice.](image-url)

The same representative images as in Figure 3 were combined with their respective pixel-by-pixel coherency maps (calculated as described for Figure 4) as Hue-Saturation-Brightness (HSB) images (H = Constant; S = Coherency; B = Original Image), such that increased amounts of "bright red" signal reflects greater coherency. Compare more bright red signal signifying greater coherency in WT (Panel A), versus less bright red signal and lesser coherency in MMP13 KO (Panel B). Coherency maps were produced using Orientation J (http://bigwww.epfl.ch/demo/orientation/).
tumor peripheries of MMP13 KO versus WT mice (Figure 6A), suggesting different collagen I microstructure between these two groups [28,29]. To validate and complement these findings, we also measured the $F_{SHG}/B_{SHG}$ ratio in these same groups and tumor-host interface regions. SHG is emitted both forwards (away from the incoming laser) and backwards (back towards the incoming laser, i.e. epi-directed) from the SHG-generating scatterers in the focal volume, and the $F_{SHG}/B_{SHG}$ ratio is an additional SHG parameter that is primarily sensitive to the spatial extent of SHG-generating scatterers along the optical axis, i.e. the effective diameter or packing arrangement/density of collagen fibrils within the SHG focal volume [4,27,30,34,42]. We found this $F_{SHG}/B_{SHG}$ ratio was significantly decreased in the E0771 tumor peripheries of MMP13 KO versus WT mice (Figure 6B). Together these two pieces of data suggest collagen I microstructure is altered in MMP13 KO versus WT mice, which may in turn relate to the observed changes in collagen I macrostructure (e.g. differences in average fiber density, apparent thickness, and organization) seen in Figures 3, 4 and 5.

Together these results suggest that stromal host MMP13 depletion alters both collagen I macrostructural (i.e. fiber arrangement, ordering, and orientation; Figures 2, 3, 4 and 5), and molecular (fibril) microstructural properties (as quantified by collagen I normalized $B_{SHG}$ and $F_{SHG}/B_{SHG}$; Figure 6) at the tumor periphery. Since WT tumor peripheries showed significantly more robust “rod like” collagen I fibers (often in a more TACS-2-like orientation), compared to the higher proportion of “diffuse” fibers in MMP13 KO animals (often in a more TACS-1-like orientation) (Figure 3), these results further suggest the possibility that MMP13 KO changes collagen I microstructure in ways that 1. Could alter collagen’s ability to form and orient larger, more rod-like fibers, and/or 2. May shift the relative balance between “diffuse” and “rod-like” collagen I phenotypes.

Stromal MMP13 knockout increases mammary tumor metastasis to lung

Collagen is a key component of the extracellular matrix (ECM) which regulates cell behavior and motility [1,8,10,43], metastasizing breast tumor cells in particular have shown a propensity to “escape” the tumor by traveling along collagen fibers [5], and particular collagen patterns or “TACS” at the breast tumor periphery are associated with poor survival [12]. Therefore the observed collagen I macro- and micro-structural changes at the tumor-host interface might be expected to affect tumor metastasis.

For these reasons, and because breast tumor metastasis to lung is associated with poor prognosis [44], we wished to determine whether the changes in collagen I macro- and micro-structural properties demonstrated above could be associated with changes in this clinically significant parameter. Indeed, we found that along with their differing collagen I macro- and micro-structural
properties (Figures 2, 3, 4, 5 and 6), our MMP13 KO animals also had roughly double the number of lung metastases compared to WT animals (Figure 7). This difference in metastasis was not due simply to differences in tumor burden between the WT and MMP13 KO animals, as tumor burden was unchanged (Figure 1).

Discussion

The ECM, and collagen in particular, are increasingly believed to play important roles in cancer etiogenesis, progression, and outcome [1-9]. Several previous reports have demonstrated that tumor cells may preferentially travel along collagen fibers [10,11], which may represent an important pathway by which invading cells metastasize [5,11]. Accordingly, collagen fibers oriented perpendicularly to the tumor boundary in what has been termed a “TACS-3” configuration, have been associated with increased invasiveness into host stroma [5] and with decreased patient survival [9,12]. In contrast, TACS-2 collagen configuration- i.e. straight “taut” fibers often parallel to the tumor boundary- was associated with regions of decreased tumor invasiveness [5].

MMPs have been implicated in many cancers including breast cancer, most likely due to their ability to modulate this collagen- and ECM-rich extracellular environment [45]. While a majority of studies have found pro-tumorigenic roles for most MMPs, a growing body of literature suggests that some or even many MMPs may have anti-cancer effects as well [46,47]. Protective effects of MMPs against tumor pathology may in part account for the relative failure of MMP inhibitors as effective chemotherapeutics [46,48,49], and this concept is further supported by evidence that endogenous tissue inhibitors of matrix metalloproteinases (TIMPs) can themselves be cancer-promoters [50-53]. MMP13 in particular has widely been found to promote cancer pathology, but a few emerging reports including this one find an apparently protective role for MMP13 in cancer and other diseases under some conditions [54,55]. Moreover, there remains limited understanding of exactly how MMP-13 interactions with collagen impact tumor pathology – for example, what structural changes result from these interactions, and how do these changes promote or protect against tumor pathology? In the studies described here, we have provided further insights into these important questions.

Herein we extended this previous work by demonstrating that in vivo genetic ablation of host MMP-13 in a mouse tumor model leads to altered collagen I macro- and micro-structure at the tumor-host interface, and increases mammary tumor metastasis to the lungs, a clinically significant functional outcome measure. This represents a direct experimental manipulation of the TACS stage of the tumor and therefore implicates stromal MMP13 as one driver of TACS evolution in breast tumors. These results are important because they help clarify the role of host MMP13 in tumor collagen dynamics, breast cancer pathogenesis, and metastasis. They are also important because this is one of few studies that have found a potentially protective effect for host MMP13 in the context of cancer pathology, and it is important to understand these intricacies of MMP13’s roles in cancer biology – i.e. when, where, and how it may have protective versus deleterious functions in cancer – in order to develop effective, targeted MMP-based therapies that do more good than harm.

Due to the fact that tumor cells migrate preferentially along aligned collagen fibers [10,11], our findings of decreased metastasis (Figure 7) associated with collagen I TACS-2 patterning (i.e. fibers parallel to the tumor

Figure 7 MMP13 knockout increases mammary tumor metastasis to lung. E0771 mouse mammary tumor cells were implanted into the mammary fat pad of congenic female C57BL/6 WT or MMP13 KO mice as described in Methods. At day 28 post-implantation, lungs were excised and processed for H&E staining for analysis of metastases. Representative images from the (A) WT and (B) MMP13 KO animals show increased metastatic burden (see arrows indicating metastases) in the MMP13 KO group. (C) Metastases/cm² were counted and averaged from 10 equidistant sampling step sections through both lobes of the lung per animal from a cohort of WT (n=6) and MMP13 KO (n=4) mice, demonstrating that MMP13 KO mice had nearly double the number of lung metastases compared to their WT counterparts (*p < .006).
MMP13 prevents the tumor stroma from progressing to a mammary tumor models [5] suggests that the lack of to what others have seen in MMP13 KO results in TACS-1 collagen patterning similar principal contributor to TACS phenotype. The fact that Figure S2), all suggest that MMP13 in particular may be a additional macro- or micro-structural collagen changes, and collagen I in particular, were not investigated. Our data here suggest further that collagen I may be a principal contributor to these MMP13-regulated changes in collagen architecture and organization, at least in some mammary tumor models. This hypothesis that changes in collagen I microstructural properties (measurable by SHG) may in turn contribute to observable changes in collagen I macrostructure requires further investigation in future studies beyond the scope of this report, but we can propose at least several ways by which this might occur. Regulation of collagen I fibril formation, fiber length and thickness, and organization is exceedingly complex and may involve numerous cellular and biochemical interactions with collagen I, just a few of which include protease activity by many MMPs, proteoglycan interactions, and/or
interactions of collagen I with other fibrillar or fibrillar-associated collagen subtypes or other ECM molecules [20,60,61]. Notably, there are several mechanisms by which MMP-13 in particular could induce collagen I microstructural changes, which further manifest themselves as macrostructural changes in collagen I fiber diameter. First, MMP-13 cleaves the collagen I amino terminal non-helical telopeptide end [62], which in turn promotes lateral fiber growth whereas leaving this site intact decreases lateral growth and is associated with initial formation of thin fibrils [63,64] – thus providing robust support for our results that WT mice (i.e. with normal MMP-13 cleavage of this site) show thicker fibers, whereas MMP13-KO mice (lacking MMP-13 cleavage of this site) have proportionately more thin (diffuse) fibers. Moreover, MMP-13 has been shown to degrade decorin [65], a proteoglycan known to be a key regulator of collagen I fiber diameter [66]. Further supporting our results, less decorin (i.e. more MMP-13) has typically been associated with thicker collagen I fibers [67,68], as we saw in the WT mice. Finally, MMP-13 can degrade collagen III which may result in altered fiber-diameter regulating interactions between collagen I and collagen III [69], or between collagen I and amino-terminal propeptide of type III procollagen which is thought to interact with Collagen I to regulate fiber diameter [70,71].

Conclusions
In this work we have directly shifted a mouse model of breast cancer from one TACS state to another by knock-out of stromal MMP13, implicating stromal MMP13 as one driver of TACS state. This also altered the metastatic output in a manner consistent with the TACS literature, although the relationship between TACS and metastatic output is not necessarily causal based upon our data. This suggests that pharmacological manipulation of MMP13 activity is an attractive avenue of exploration in order to manipulate TACS state and hence attempt to alter metastatic output. In total, these novel findings that MMP13 may have beneficial roles in cancer biology by significantly altering collagen I dynamics and metastatic potential, help to further clarify MMP13’s potentially protective roles in tumor pathology and thus facilitate future design of more specifically targeted and effective MMP-based therapies that minimize risks to the patient.

Additional files

Additional file 1: Figure S1. Decreased MMP13 expression in MMP13 KO tumors. WT and MMP13 KO mice were implanted with E0771 mammary tumors as described (A). Following excision of the primary tumor, MMP13 gene expression was assessed by quantitative PCR (qPCR) and normalized to 1, showing decreased MMP13 expression in MMP13 KO versus WT tumors (p < .03) in the same cohort of WT (n=6) and MMP13 KO (n=4) mice. In addition, following immunofluorescence labeling for MMP13, the tumors from the (B) WT mice had peritumor MMP13+ cell bodies which were not apparent in the tumors from the (C) MMP13 KO mice. To assure details are visible for illustrative purposes, the original grayscale MMP13 immunofluorescence is shown with “Green” LUT applied in ImageJ, with levels (screen stretch) linear and set the same for both images. Additional file 2: Figure S2. MMP13 at the tumor periphery is patterned like Collagen I in TACS-2. MMP13 immunofluorescence of adjacent sections of the same WT tumor as depicted in Figures 3A and 5A illustrates that MMP13 protein expression appears to align with the TACS-2 patterned Collagen I fibers depicted in Figures 3A and 5A, which are robust and oriented in a “barrier like” fashion around the tumor periphery, as is the MMP13 labeling shown here. Fiber banding patterns are visible amidst the MMP13 fluorescence labeling in this image. For illustrative purposes, the original grayscale MMP13 immunofluorescence is shown with a spectral lookup table (‘Fire’ LUT in ImageJ) applied and linear screen stretch (levels) set to assure details are visible for qualitative presentation.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SWP conceived and designed studies, acquired and analyzed data, and wrote the manuscript. JMS, KB, and GLA acquired and analyzed data. EBB conceived and designed studies and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank the reviewers for their helpful suggestions on this manuscript. We thank Dr. Ryan M. Burke and Clark Burns for technical assistance. We thank Dr. Kelley S. Madden for helpful discussions and Dr. Stephen M. Krane for providing the MMP13 knockout mice. This work was supported by Department of Defense Breast Cancer Research Program (DoD BCRP) Era of Hope Scholar Research Award W81XWH-09-1-0405 (to EBB), National Institutes of Health (NIH) Director’s New Innovator Award 1DP2 OD006501-01 (to EBB), and NIH Exploratory Developmental Research Grant Award R21DA30256 (to SWP). This paper is subject to the NIH Public Access Policy.

Received: 22 April 2013 Accepted: 28 August 2013
Published: 5 September 2013

References
1. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395–406.
2. Spano D, Zollo M: Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 2012, 29(4):381–395.
3. Wolf K, Alexander S, Schacht V, Coussens LM, von Andrian UH, van Rheenen J, Deryugina E, Friedl P: Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol 2009, 20(8):931–941.
4. Han X, Burke RM, Zettel ML, Tang P, Brown EB: Second harmonic properties of tumor collagen: determining the structural relationship between reactive stroma and healthy stroma. Opt Express 2008, 16(9):1846–1859.
5. Provenzano PP, Elceiire KW, Campbell JM, Inman DR, White JG, Keely PJ: Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006, 4(1):38.
6. Hompland T, Erikson A, Lindgren M, Lindmo T, de Lange Davies C: Second-harmonic generation in collagen as a potential cancer diagnostic parameter. J Biomed Opt 2008, 13(5):054050.
7. Brown E, McKeever T, DiTommaso E, Pluen A, Seed B, Boucher Y, Jain RK: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003, 9(6):796–800.
8. Schedin P, Keely PJ: Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 2011, 3(1):a003239.
27. Perry SW, Han X, Brown EB: A Tensor Approach for Local Structure Analysis in Multi-Dimensional Images. In Proceedings 3D Image Analysis and Synthesis. Springer Berlin Heidelberg, 2008, 107(3):85–92.

28. Christensen IJ, Edwards DR, Werb Z, Lund LR: Matrix metalloproteinase 13 exhibits a protective role in lung metastasis of melanoma cells by local down-regulation of matrix metalloproteinases. Cancer Res 2005, 65(16):7038–7043.

29. Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW: Regulation of matrix metalloproteinase expression in breast cancer cells. Cancer Res 2003, 63(18):5850–5857.

30. Hojilla CV, Mohammed FF, Khokha R: Matrix metalloproteinase-13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS ONE 2010, 5(8):e12059.

31. Mohler W, Millard AC, Campagnola PJ: Second harmonic generation imaging of endogenous structural proteins. Methods 2003, 29(3):197–109.

32. Campagnola PJ, Loew LM: Second-harmonic imaging microscopy for visualizing biomolecular arrays in cells, tissues and organisms. Nat Biotechnol 2003, 21(11):1356–1360.

33. Merz J, Monea L: Second harmonic generation by focused excitation of inhomogeneously distributed scatterers. Opt Commun 2001, 196(6):1325–30.

34. Parnats P, Maloney J, Wu D, Fraser SE: Second harmonic generating (SHG) nanoprobes for in vivo imaging. Proc Natl Acad Sci USA 2010, 107(3):1435–1450.

35. Pantazis N, Nayar SK, Kinter RJ, Camarillo DM, Horchler AJ: High intensity focused ultrasound (HIFU) imaging: Phys Chem Chem Phys 2009, 12(11):13484–13498.

36. Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukushima D, Jain RK: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001, 7(10):864–868.

37. Edin C, Gullbert T, Alkanni A, Borysinska OP, Fleury V, Le Grand Y: Collagen and myosin characterization by orientation field second harmonic microscopy. Opt Express 2008, 16(20):16151–16165.

38. Plokonik SV, Millard AC, Campagnola PJ, Mohler WA: Characterization of the myosin-based source for second-harmonic generation from muscle sarcomers. Biophys J 2006, 90(2):693–703.

39. Su PJ, Chen WL, Chen YF, Dong CY: Determination of collagen nanostructure from second-order susceptibility tensor analysis. Biophys J 2011, 100(8):2053–2062.

40. Taha F, Recher G, Roude D: Estimation of helical angles of myosin and collagen by second harmonic generation imaging microscopy. Opt Express 2007, 15(19):12386–12295.

41. Lacomb R, Nadarnykh O, Townsend SS, Campagnola PJ: Phase Matching considerations in Second Harmonic Generation from tissues: Effects on emission directonality, conversion efficiency and observed morphology. Opt Commun 2008, 281(7):1823–1832.

42. Ghajar CM, Bissell MJ: Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 2008, 130(6):1105–1118.

43. Welter S, Jacobs J, Kibek T, Totsch M, Starnagis P: Luminal metastases of breast cancer. When is resection indicated. Eur J Cardiothorac Surg 2008, 34(12):1228–1234.

44. Westermark J, Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J 1999, 13(8):781–792.

45. Martin MD, Matriasin LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007, 26(3–4):777–772.

46. Noel A, Gutierrez-Fernandez A, Sounni NE, Behrendt N, Maquoi E, Lund IK, Cal G, Unner H-G, Hoyer-Hansen S, Lopez-Otin C: New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Frontiers in pharmacology 2012, 3:140.

47. Zucker S, Cao J: Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer biology & therapy 2009, 8(24):2371–2373.

48. Overall CM, Kielfield O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6(3):227–239.

49. Bourboulia D, Sterlet-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010, 20(3):161–168.

50. Goldrevska M, Sevilkova M, Mozocova B, Sarmitkova M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 2012, 50(1):12–19.

51. Jiad Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21(4):2455–2522.

52. Hjoll CV, Mohammed FF, Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2009, 90(10):1718–1721.

53. Fukuda H, Mochizuki S, Abe H, Okano J, Hara-Miyauchi C, Okano H, Yamaguchi N, Nakayama M, D’armiento J, Okada Y: Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production. Br J Cancer 2011, 105(10):1615–1624.

54. Tarin C, Gomez M, Calvo E, Lopez JA, Zaragoza C: Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular
endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29(1):27–32.

56. Chang HJ, Yang MJ, Yang YH, Hou MF, Hseuh EJ, Lin SR. MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep 2009, 22(5):1119–1127.

57. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996, 149(1):273–282.

58. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997, 57(21):4882–4888.

59. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 2000, 291(2):137–155.

60. Saeidi N. On the control of collagen fibril organization and morphology. Mechanical Engineering Dissertations Paper 7. http://iris.lib.neu.edu/cgi/viewcontent.cgi?article=1006&context=mech_eng_diss 2009.

61. Bode M. Characterization of Type I and Type III collagens in human tissues. Thesis Dissertation, Oulu University Library. http://herkules.oulu.fi/isbn9514255534/isbn9514255534.pdf 2000.

62. Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP, Liu X, Wu H, Jaenisch R, Eeckhout Y. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem 1996, 271(45):28509–28515.

63. Silver FH, Freeman JW, Seehra GP. Collagen self-assembly and the development of tendon mechanical properties. J Biomech 2003, 36(10):1529–1553.

64. Comper WD, Veis A. Characterization of nuclei in in vitro collagen fibril formation. Biopolymers 1977, 16(10):2133–2142.

65. Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier JP, Martel-Pelletier J. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther 2006, 8(1):R26.

66. Vogel KG, Paulsson M, Heingard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 1984, 223(3):587–597.

67. Hakkinen L, Straszburger S, Kahari VM, Scott PG, Eichstetter I, Lazzaro RV, Larjava H. A role for decorin in the structural organization of periodontal ligament. Lab Invest 2000, 80(12):1869–1880.

68. Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET, Soslowsky LJ, Lazzaro RV, Birk DE. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006, 98(4):1436–1449.

69. Cameron GI, Alberts LS, Laing JH, Weiss TJ. Structure of type I and type III heterotypic collagen fibrils: an X-ray diffraction study. J Struct Biol 2002, 137(1–2):15–22.

70. Fleischmajer R, Perlish JS, Burgeson RE, Shaikh-Bahai F, Timpl R. Type I and type II collagen interactions during fibrillogenesis. Ann N Y Acad Sci 1990, 580:161–175.

71. Romanic AM, Adachi E, Kadler KE, Hojima Y, Prockop DJ. Copolymerization of pNcollagen III and collagen I. pNcollagen III decreases the rate of incorporation of collagen I into fibrils, the amount of collagen I incorporated, and the diameter of the fibrils formed. J Biol Chem 1991, 266(19):12703–12709.

doi:10.1186/1471-2407-13-411
Cite this article as: Perry et al.: Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells. BMC Cancer 2013 13:411.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit